Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

CD 155, an onco‐immunologic molecule in human tumors

Open access
Gao, Jian, Zheng, Qianqian, Xin, Na, Wang, Wei, Zhao, Chenghai·2017·Cancer Science

Abstract

CD 155 is the fifth member in the nectin‐like molecule family, and functions as the receptor of poliovirus; therefore, CD 155 is also referred to as necl‐5, or PVR. As an immunoglobulin‐like adhesion molecule, CD 155 is involved in cell motility, and natural killer and T cell‐mediated immunity. CD 155 is barely or weakly expressed in various normal human tissues, but frequently overexpressed in human malignant tumors. CD 155 overexpression promotes tumor cell invasion and migration, and is associated with tumor progression and poor prognosis. As the ligand for both costimulatory receptor CD 226 and coinhibitory receptor TIGIT and CD 96 on natural killer and T cells, CD 155 seems to play a dual role in oncoimmunity. However, some recent studies indicate that CD 155 overexpression may induce tumor immune escape. Taken together, CD 155 may be considered as a target for the treatment of tumors with CD 155 overexpression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cas.13324

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 199

Metadata

Authors
Gao, J., Zheng, Q., Xin, N., Wang, W., & Zhao, C.
Venue
Cancer Science
Publisher
Wiley
Published
2017-08-18
Volume
108
Issue
10
Pages
1934-1938
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
OpenAlex
W2737469573
Cited by
199
References
3
FWCI
6.14
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD 155, an onco‐immunologic molecule in human tumors. https://app.cochat.ai/papers/10.1111/cas.13324
The paper
Gao, J., Zheng, Q., Xin, N., Wang, W., & Zhao, C. (2017). CD 155, an onco‐immunologic molecule in human tumors. Cancer Science. https://doi.org/10.1111/cas.13324

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.